Marijo Bilusic, MD, PhD

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Marijo Bilusic, MD, PhD, discusses key considerations and unanswered questions regarding the use of PARP inhibitors in patients with prostate cancer.

Marijo Bilusic, MD, PhD, discusses key trials in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Marijo Bilusic, MD, PhD, discusses updates seen in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.